OSIP-486823 (OSIP 486823) (Synonyms: OSIP 486823; OSIP486823; CP248) |
Katalog-Nr.GC33163 |
OSIP-486823 (OSIP 486823) ist ein neuartiges Mikrotubuli-interferierendes Mittel mit deutlichen biologischen Wirkungen sowohl auf Proteinkinase G (PKG) als auch auf Mikrotubuli.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 200803-37-8
Sample solution is provided at 25 µL, 10mM.
OSIP-486823 is a novel microtubule-interfering agent with distinct biological effects on both protein kinase G (PKG) and microtubules.
OSIP486823 inhibits growth and induce apoptosis in SW480 human colon cancer cells, with IC50 of 0.1 μM. OSIP-486823 (OSIP486823) causes depolymerization of microtubules in interphase cells, inhibit spindle formation in mitotic cells, and induce multinucleated cells. Exisulind and the potent synthetic derivative OSIP-486823 are members of a new class of drugs known as selective apoptotic antineoplastic drugs that target cyclic guanosine 3′,5′-monophosphate phosphodiesterases (cGMP-PDE). OSIP-486823 also disrupts microtubule polymerization, perturbs mitotic spindle function, and arrests cells in mitosis in human glioma cells[1].
[1]. Xiao D, et al. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. Mol Cancer Ther. 2006 Jan;5(1):60-7.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *